nach oben

Rheumatology International

Erschienen in:

01.12.2012 | Short Communication

Interferon regulatory factor (IRF)-5: a potential therapeutic target for ankylosing spondylitis

verfasst von: Wang-Dong Xu, Dong-Qing Ye

Erschienen in: Rheumatology International | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Ankylosing spondylitis is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which can lead to structural and functional impairments and a decrease in quality of life. New imaging techniques and therapies have substantially changed the management of this disease in the past decade. Whether inhibition of radiographic progression and structural damage can be reached with available drugs is as yet unclear. Furthermore, treatment with non-steroidal anti-inflammatory agents and physiotherapy remains an important approach to long-term management of patients with ankylosing spondylitis. The new treatment options with IRF-5 seem to be a breakthrough for patients’ refractory to conventional and feasible treatment.

Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379–1390PubMedCrossRef

Honda K, Taniguchi T (2006) IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6:644–658PubMedCrossRef

Barnes BJ, Kellum MJ, Field AE et al (2002) Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Bio 22:5721–5740CrossRef

Schoenemeyer A, Barnes BJ, Mancl ME et al (2005) The interferon regulatory factor, IRF5, is a central mediator of Toll-like receptor 7 signaling. J Bio Chem 280:17005–17012CrossRef

Takaoka A, Yanai H, Kondo S et al (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243–249PubMedCrossRef

Paun A, Reinert JT, Jiang ZZ et al (2008) Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J Bio Chem 283:14295–14308CrossRef

Barnes BJ, Richards J, Mancl M et al (2004) Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Bio Chem 279:45194–45207CrossRef

Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25:383–392PubMedCrossRef

Graham RR, Kyogoku C, Sigurdsson S et al (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. PANS 104:6758–6763CrossRef

10.

Hu GD, Barnes BJ (2006) Interferon regulatory factor-5-regulated pathways as a target for colorectal cancer therapeutics. Expert Rev 5:775–784

11.

Yang XM, Zhao D, Su ZW et al. (2010) Apoptosis and polarization of T cells in ankylosing spondylitis patients. China Trop Med 10:88-89, 91

12.

Zhang X, Liu JX, Li HH et al (2010) The expression of IRF5 gene in SLE patients. Chin J Lab Diagn 14:1082–1084

13.

Ma XB, Wang HT, Chang JW et al (2006) Interferon regulatory factor and Th cell differentiation. Modern Immunol 26:76–80

14.

Tang YJ, Q Q, Huang XF et al (2007) IRF7 expression and its association with systemic lupus erythematosus. J East Chin Normal Univ 4:111–117

15.

Cao YH, Zhang SJ, Zhou YC (2006) Interferon regulatory factor family and immune regulation. Chem Life 26:378–389

16.

François RJ, Neure L, Sieper J et al (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef

17.

Yang ZX, Liang Y, Zhu Y et al (2007) Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis. Clin Exp Immunol 149:48–55PubMedCrossRef

18.

Dideberg V, Kristjansdottir G, Milani L et al (2007) An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 16:3008–3016PubMedCrossRef

19.

Kozyrev SV, Lewén S, Reddy PL et al (2007) Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 56:1234–1241PubMedCrossRef

20.

Fan JH, Gao LB, Pan XM et al (2010) Association between IRF-5 polymorphisms and risk of acute coronary syndrome. DNA Cell Bio 29:19–23CrossRef

21.

Takaoka A, Yanai H, Kondo S et al (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243–249PubMedCrossRef

22.

Kristjansdottir G, Sandling JK, Bonetti A et al (2008) Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 45:362–369PubMedCrossRef

23.

Ito I, Kawaguchi Y, Kawasaki A et al (2009) Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheuma 60:1845–1850CrossRef

24.

Miceli-Richard C, Gestermann N, Ittah M et al (2009) The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren’s syndrome. Arthritis Rheum 60:1991–1997PubMedCrossRef

25.

Miceli-Richard C, Comets E, Loiseau P (2007) Association of an IRF5 gene functional polymorphism with Sjögren’s syndrome. Arthritis Rheum 56:3989–3994PubMedCrossRef

26.

Sigurdsson S, Nordmark G, Göring HH et al (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 Genes are associated with systemic lupus erythematosus. Am S Hum Genet 76:528–537CrossRef

27.

Graham RR, Kozyrev SV, Baechler EC et al (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555PubMedCrossRef

28.

Song WQ, Li HH, Chen HB et al (2009) Relationship between polymorphism sites of IRF5, TLR-9 and SLE patients in Shandong Han population. Nat Med J Chin 89:3042–3083

29.

Kelly JA, Kelley JM, Kaufman KM et al (2008) Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immunity 9:187–194PubMedCrossRef

30.

Shin HD, Sung YK, Choi CB et al (2007) Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population. Arthritis ResTher 9:1–5

31.

Kawasaki A, Kyogoku C, Ohashi J et al (2008) Association of IRF5 Polymorphisms With Systemic Lupus Erythematosus in a Japanese Population. Arthritis Rheum 58:826–834PubMedCrossRef

32.

Shimane K, Kochi Y, Yamada R et al. (2009) A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. Ann Rheum Dis 377–383

33.

Feng D, Stone RC, Eloranta ML et al (2010) Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 62:562–573PubMed

34.

Sigurdsson S, Padyukov L, Kurreeman FS et al (2007) Association of a Haplotype in the Promoter Region of the Interferon Regulatory Factor 5 Gene With Rheumatoid Arthritis. Arthritis Rheum 56:2202–2210PubMedCrossRef

35.

Rönnblom L, Eloranta ML, Alm GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 54:408–420PubMedCrossRef

Titel: Interferon regulatory factor (IRF)-5: a potential therapeutic target for ankylosing spondylitis
verfasst von: Wang-Dong Xu
Dong-Qing Ye
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 12/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-011-2113-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Genetic polymorphisms of the DNA repair gene UNG are associated with the susceptibility of rheumatoid arthritis

Investigation of the change in CD4+ T cell subset in children with Henoch–Schonlein purpura

Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women’s Health Initiative Calcium plus Vitamin D trial

Hysterical paralysis after spinal surgery

Prognostic factors for long-term work disability due to musculoskeletal disorders